New hope for cancer patients: gentler liver treatment tested
NCT ID NCT07378761
Summary
This study aims to find a better way to treat severe liver inflammation that can occur as a side effect of powerful cancer immunotherapies. It will compare a standard steroid treatment against a different drug called ursodeoxycholic acid (UDCA), which may have fewer side effects. The goal is to control the liver damage so patients can potentially resume their cancer treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE-MEDIATED CHOLESTASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
APHP Paul Brousse
Paris, France
-
CHU Bordeaux
Bordeaux, France
Contact
-
CHU Montpellier
Montpellier, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Poitiers
Poitiers, France
-
CHU Toulouse
Toulouse, France
-
HCL Croix Rousse
Lyon, France
Conditions
Explore the condition pages connected to this study.